Found 8 matching trials
A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
PHASE1This study was a phase Ib study of the safety and pharmacokinetics/pharmaco...
Location
Fudan University Shanghai Cancer Center
Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
PHASE2This is a randomized open label dose finding study to evaluate the efficacy...
Location
Community Hospital of Anderson
A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.
PHASE2This was a randomized, open-label, active-controlled, dose-finding, phase I...
Location
Fudan University Shanghai Cancer Center
Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
PHASE3This is a randomized, multi-center, single dose, open-label and Neulasta co...
Location
University of California Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center (JCCC)
Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
PHASE3This is a randomized, double-blind and placebo controlled phase 3 study to ...
Study to Compare the Efficacy and Safety of F-627 and GRAN®
PHASE3A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Trial ...
Location
Fudan University Shanghai Cancer Center
Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer
PHASE2A multi-cohort, open-label, multicenter exploratory clinical study of Bemal...
Location
the Second Affiliated Hospital of Medical College of Zhejiang University
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
PHASE1A Phase I, dose escalation study to evaluate the safety and pharmacokinetic...
Location
Multiple Locations